Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients

C.S.E. Verbrugge; Y.G. Assaraf; B.A.C. Dijkmans; G.L. Scheffer; M.C.M. Al; D. den Uyl; R. Oerlemans; E.T. Chan; C.J. Kirk; G.J. Peters; J.W. van der Heijden; T.D. de Gruijl; R.J. Scheper; G. Jansen

doi:10.1124/jpet.111.187542

Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients

C.S.E. Verbrugge, Y.G. Assaraf, B.A.C. Dijkmans, G.L. Scheffer, M.C.M. Al, D. den Uyl, R. Oerlemans, E.T. Chan, C.J. Kirk, G.J. Peters, J.W. van der Heijden, T.D. de Gruijl, R.J. Scheper, G. Jansen

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	174-182
Journal	The Journal of Pharmacology and Experimental Therapeutics
Volume	341
Issue number	1
DOIs	https://doi.org/10.1124/jpet.111.187542
Publication status	Published - 2012

Access to Document

10.1124/jpet.111.187542

http://jpet.aspetjournals.org/content/early/2012/01/10/jpet.111.187542

Cite this

Verbrugge, C. S. E., Assaraf, Y. G., Dijkmans, B. A. C., Scheffer, G. L., Al, M. C. M., den Uyl, D., Oerlemans, R., Chan, E. T., Kirk, C. J., Peters, G. J., van der Heijden, J. W., de Gruijl, T. D., Scheper, R. J., & Jansen, G. (2012). Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients. The Journal of Pharmacology and Experimental Therapeutics, 341(1), 174-182. https://doi.org/10.1124/jpet.111.187542

Verbrugge, C.S.E. ; Assaraf, Y.G. ; Dijkmans, B.A.C. et al. / Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients. In: The Journal of Pharmacology and Experimental Therapeutics. 2012 ; Vol. 341, No. 1. pp. 174-182.

@article{b055297a098f4333b369e53060a3605b,

title = "Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients",

author = "C.S.E. Verbrugge and Y.G. Assaraf and B.A.C. Dijkmans and G.L. Scheffer and M.C.M. Al and {den Uyl}, D. and R. Oerlemans and E.T. Chan and C.J. Kirk and G.J. Peters and {van der Heijden}, J.W. and {de Gruijl}, T.D. and R.J. Scheper and G. Jansen",

year = "2012",

doi = "10.1124/jpet.111.187542",

language = "English",

volume = "341",

pages = "174--182",

journal = "The Journal of Pharmacology and Experimental Therapeutics",

issn = "0022-3565",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "1",

}

Verbrugge, CSE, Assaraf, YG, Dijkmans, BAC, Scheffer, GL, Al, MCM, den Uyl, D, Oerlemans, R, Chan, ET, Kirk, CJ, Peters, GJ, van der Heijden, JW, de Gruijl, TD , Scheper, RJ & Jansen, G 2012, 'Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients', The Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 174-182. https://doi.org/10.1124/jpet.111.187542

Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients. / Verbrugge, C.S.E.; Assaraf, Y.G.; Dijkmans, B.A.C. et al.

In: The Journal of Pharmacology and Experimental Therapeutics, Vol. 341, No. 1, 2012, p. 174-182.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients

AU - Verbrugge, C.S.E.

AU - Assaraf, Y.G.

AU - Dijkmans, B.A.C.

AU - Scheffer, G.L.

AU - Al, M.C.M.

AU - den Uyl, D.

AU - Oerlemans, R.

AU - Chan, E.T.

AU - Kirk, C.J.

AU - Peters, G.J.

AU - van der Heijden, J.W.

AU - de Gruijl, T.D.

AU - Scheper, R.J.

AU - Jansen, G.

PY - 2012

Y1 - 2012

U2 - 10.1124/jpet.111.187542

DO - 10.1124/jpet.111.187542

M3 - Article

SN - 0022-3565

VL - 341

SP - 174

EP - 182

JO - The Journal of Pharmacology and Experimental Therapeutics

JF - The Journal of Pharmacology and Experimental Therapeutics

IS - 1

ER -

Verbrugge CSE, Assaraf YG, Dijkmans BAC, Scheffer GL, Al MCM, den Uyl D et al. Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients. The Journal of Pharmacology and Experimental Therapeutics. 2012;341(1):174-182. doi: 10.1124/jpet.111.187542